I wonder what the chances are that we might skip t

I wonder what the chances are that we might skip the Phase 3 and go to Phase 4. With the new FDA and a drug that's safe, the only treatment option, and (assuming) Breakthrough Therapy Designation; I would think that B-OM could be approved for use without a Phase 3.

"My take on today's PR is that IPIX mgmt is VERY confident in favorable top line results of B-OM and they are sending out a message to big pharma that whatever deals that are currently on the table need to get sweetened up soon or they will either lose out to one of their competitors or it will be much more costly license after a successful phase 3. I believe IPIX is going to focus a majority of resources bringing B-OM to the market with or without big pharma. As shareholders we win either way. Get a decent deal now and collect a nice stream of royalty income going forward with a nice chunk of cash to advance P and K until one or both of them are entered into a similar royalty agreement/s. If IPIX mgmt feel that the current B-OM deals on the table do not provide the proper value to shareholders than IPIX will focus on getting B-OM through phase 3. Ultimately this would be the most lucrative option for shareholders even with some slight diluting. Pay up now or pay much more later. I expect great top line results out soon followed by a quiet period on B while a deal gets consummated. In the mean time P and K advancement will continue in parallel. IMHO" - Mo